Paper Details

  1. Home
  2. Paper Details

Therapy of Vestibular Paroxysmia, Superior Oblique Myokymia, and Ocular Neuromyotonia.

Author: BrandtThomas, DieterichMarianne, FeilKatharina, StruppMichael

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This study discusses neurovascular compression syndromes, characterized by recurrent attacks of neurological symptoms due to nerve compression by an artery. Treatment recommendations, based on single cases or small case series, suggest that sodium channel blockers like carbamazepine or oxcarbazepine are effective in most patients with vestibular paroxysmia, superior oblique myokymia, or ocular neuromyotonia. Surgical decompression may be considered for patients who do not respond to pharmacotherapy.
Paper Details　
Original Abstract of the Article :
Neurovascular compression syndromes are characterized by recurrent attacks of neurological symptoms and clinical signs depending on the cranial nerve affected. It is assumed that pulsatile compression of the nerve is caused mainly by an artery. The result is segmental demyelination of the transition...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11940-016-0417-2

データ提供：米国国立医学図書館（NLM）

Neurovascular Compression Syndromes: A Camel's Guide to Treatment

Neurovascular compression syndromes are characterized by recurrent neurological symptoms and signs caused by pulsatile compression of a cranial nerve by an artery. This review delves into the treatment of three specific neurovascular compression syndromes: vestibular paroxysmia, superior oblique myokymia, and ocular neuromyotonia. The authors discuss the pathophysiology of these conditions and highlight the effectiveness of sodium channel blockers, such as carbamazepine and oxcarbazepine, as a primary treatment approach. They also mention alternative therapies, such as other sodium channel blockers and beta blockers, as well as surgical decompression in cases where pharmacotherapy is ineffective.

Sodium Channel Blockers: A Potential Oasis in the Desert of Neurovascular Compression Syndromes

This review offers a comprehensive overview of treatment options for three specific neurovascular compression syndromes. The authors' emphasis on sodium channel blockers as the primary treatment approach, alongside other alternatives, provides valuable insights for clinicians managing these challenging conditions. The research highlights the importance of individualized care, tailoring treatment strategies to meet the specific needs of each patient.

Neurovascular Compression Syndromes: Understanding the Complexities of the Nervous System

Neurovascular compression syndromes demonstrate the intricate and delicate nature of the nervous system. This review provides valuable insights into the pathophysiology of these conditions and the effectiveness of different treatment approaches. It's crucial to seek medical advice and follow recommended guidelines for managing these complex disorders.

Dr.Camel's Conclusion

The treatment of neurovascular compression syndromes is a journey through a complex and often challenging landscape. This review provides a valuable roadmap for clinicians, highlighting the effectiveness of sodium channel blockers and other therapies. By understanding the complexities of these conditions and utilizing the appropriate treatment strategies, we can strive to improve the lives of patients experiencing these debilitating symptoms.

Date :
  1. Date Completed 2016-06-16
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

27306762

DOI: Digital Object Identifier

10.1007/s11940-016-0417-2

Related Literature

Article Analysis
・Side Effects of oxcarbazepine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.